We are live on !
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$176M
Turnover
21.05%
1-Year Est. Return
123.21%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+123.21%
3 Year Est. Return
+348.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$176M
AUM Growth
+$20.3M
(+13%)
Cap. Flow
+$13.7M
Cap. Flow % of AUM
Cap. Flow %
7.8%
Top 10 Holdings %
Top 10 Hldgs %
93.29%
Holding
19
New
3
Increased
5
Reduced
3
Closed
1
Avg Time Held
Equity + Options
1.2
years
Top 10 Avg Time Held
Equity + Options
1.1
years
Top 20 Avg Time Held
Equity + Options
1.2
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
1.1
years
Top 20 Avg Time Held Equity only
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
enGene Therapeutics
ENGN
|
+$27.2M |
| 2 |
The Kraft Heinz Company
KHC
|
+$7.85M |
| 3 |
Outset Medical
OM
|
+$2.7M |
| 4 |
CarMax
KMX
|
+$762K |
| 5 |
Connect Biopharma Holdings
CNTB
|
+$399K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$10.1M |
| 2 |
Oramed Pharmaceuticals
ORMP
|
+$9.16M |
| 3 |
Kezar Life Sciences
KZR
|
+$5.35M |
| 4 |
Atea Pharmaceuticals
AVIR
|
+$529K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.13% |
| 2 | Consumer Discretionary | 10.31% |
| 3 | Consumer Staples | 9.02% |
| 4 | Miscellaneous | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Aclaris Therapeutics
ACRS
$509M
| $63.3M | 35.98% |
11,975,000
-2,275,000
| -16% | -$10.1M |
2023 Q4
10 quarters
|
|
|
2
Atea Pharmaceuticals
AVIR
$351M
| $32.3M | 18.36% |
6,952,330
-106,327
| -2% | -$529K |
2023 Q2
12 quarters
|
|
|
3
enGene Therapeutics
ENGN
$108M
| $11.5M | 6.55% |
+6,669,908
| New | +$27.2M |
2026 Q2
0 quarters
|
|
|
4
The Kraft Heinz Company
KHC
$27.5B
| $11M | 6.24% |
465,000
+340,000
| +272% | +$7.85M |
2026 Q1
1 quarter
|
|
|
5
Outset Medical
OM
$72.7M
| $10.9M | 6.18% |
2,519,701
+617,500
| +32% | +$2.7M |
2025 Q4
2 quarters
|
|
|
6
CarMax
KMX
$7.32B
| $9.12M | 5.18% |
172,500
+17,500
| +11% | +$762K |
2025 Q4
2 quarters
|
|
7
Tilly's
TLYS
$140M
| $9.03M | 5.13% |
2,150,000
| – | – |
2026 Q1
1 quarter
|
|
8
PMV Pharmaceuticals
PMVP
$67.9M
| $7.14M | 4.06% |
5,330,000
+10,000
| +0.2% | +$12.8K |
2024 Q1
9 quarters
|
|
9
Instil Bio
TIL
$39.7M
| $4.96M | 2.82% |
645,600
| – | – |
2024 Q1
9 quarters
|
|
10
Target
TGT
$69.7B
| $4.9M | 2.78% |
37,500
| – | – |
2025 Q3
3 quarters
|
|
|
11
Oramed Pharmaceuticals
ORMP
$169M
| $4.17M | 2.37% |
866,269
-2,300,962
| -73% | -$9.16M |
2023 Q1
13 quarters
|
|
12
Janux Therapeutics
JANX
$1.02B
| $2.38M | 1.35% |
154,961
| – | – |
2026 Q1
1 quarter
|
|
13
Pliant Therapeutics
PLRX
$55.4M
| $1.76M | 1% |
1,546,137
| – | – |
2025 Q4
2 quarters
|
|
|
14
Connect Biopharma Holdings
CNTB
$56.7M
| $1.36M | 0.78% |
573,287
+164,400
| +40% | +$399K |
2023 Q4
10 quarters
|
|
15
ImageneBio Inc
IMA
$46M
| $1.18M | 0.67% |
200,730
| – | – |
2024 Q2
8 quarters
|
|
16
PUT
Walmart Inc
WMT
$941B
| $386K | 0.22% |
335
| – | – |
2025 Q3
3 quarters
|
|
17
PUT
Core Scientific
CORZ
$4.43B
| $298K | 0.17% |
+800
| New | +$18.8K |
2026 Q2
0 quarters
|
|
18
PUT
Tesla
TSLA
$1.45T
| $270K | 0.15% |
+375
| New | +$149K |
2026 Q2
0 quarters
|
|
|
19
DELISTED
Kezar Life Sciences
KZR
| – | – |
-720,787
| Closed | -$5.35M | – |
|
Similar funds
LFA
BMCM
KRAVCF
CC
ADMI
DF
OL
MP
BML Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, BML Capital Management held 19 positions worth $176M, up 13% from $156M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
BML Capital Management deployed $13.7M of net new capital in Q2 2026, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was enGene Therapeutics: 6,669,908 shares worth $11.5M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $10.1M trimmed.
- BML Capital Management's largest Q2 2026 buy was enGene Therapeutics: 6,669,908 shares worth $11.5M.
- BML Capital Management added most to The Kraft Heinz Company in Q2 2026, an estimated $7.85M increase.
- BML Capital Management's biggest Q2 2026 reduction was Aclaris Therapeutics, cutting an estimated $10.1M.
- BML Capital Management fully exited Kezar Life Sciences in Q2 2026, selling an estimated $5.35M.
- BML Capital Management's ten largest holdings make up 93% of its $176M portfolio in Q2 2026.
- BML Capital Management opened 3 new positions and closed 1 in Q2 2026.
- BML Capital Management's portfolio value rose 13% quarter-over-quarter to $176M.
Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.